Voyager Therapeutics, Inc. (VYGR) Cash Flow Statement
Voyager Therapeutics, Inc. (VYGR) generated -$120.6M of operating cash flow over the twelve months to 2026-06-30, spent $847000 on capital expenditure and had free cash flow of -$121.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VYGRVoyager Therapeutics, Inc.Follow VYGR — free
—
Price chart with a free account
- Market cap
- 107.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 41.3 | -42.5 | -61.4 | -15.9 | 48.7 | -96.7 | -53.5 | -12.5 | 77.9 | -15.3 | -132.5 | -120.6 | |
| Capital expenditure | 1.0 | 5.0 | 4.0 | 4.3 | 7.7 | 12.1 | 1.6 | 2.5 | 3.3 | 3.5 | 2.6 | -0.8 | |
| Free cash flow | 40.3 | -47.5 | -65.3 | -20.2 | 40.9 | -108.8 | -55.1 | -15.0 | 74.7 | -18.8 | -135.1 | -121.4 | |
| Stock-based compensation | 4.0 | 6.3 | 9.2 | 15.7 | 15.6 | 14.9 | 11.3 | 9.3 | 11.2 | 14.8 | 14.8 | — |
USD millions · SEC XBRL
Voyager Therapeutics, Inc. — questions
- What is Voyager Therapeutics, Inc.'s operating cash flow?
- -$120.6M over the twelve months to 2026-06-30.
- How much does Voyager Therapeutics, Inc. spend on capital expenditure?
- $847000 over the twelve months to 2026-06-30.
- What is Voyager Therapeutics, Inc.'s free cash flow?
- -$121.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Voyager Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.